RESUMEN
The present study aimed to evaluate the efficacy of traditionally used antibacterial plants (Euphorbia prostrata, Schinus molle, Brickellia veronicaefolia and Lepidium virginicum) in Santa Rosa Range in Guanajuato against major mastitis-causing pathogens. The selected plants were phytochemically screened for alkaloids, flavonoids, polyphenols, saponins, anthraquinone, cardiac glycosides, steroids and terpenoids. Moreover, to achieve the main purpose of the present research, extracts of selected plants were tested for in vitro antibacterial activity against Staphylococcus aureus, Escherichia coli, Shigella spp., Bacillus subtilis, Clavibacter spp., Proteus vulgaris and Salmonella spp. All these bacterial were isolated from clinical mastitis in dairy cows. The results indicated that the ethanolic extract of the aerial part of L. virginicum exhibited the strongest antimicrobial activity, and it could be potential candidate specie for the development of novel veterinary drugs with low cost and fewer side effects.
O presente estudo teve como objetivo investigar a eficácia de plantas antibacterianas tradicionalmente usadas (Euphorbia prostrata, Schinus molle, Brickellia veronicaefolia e Lepidium virginicum) na cordilheira Santa Rosa, em Guanajuato, contra os principais patógenos causadores de mastite. As plantas selecionadas foram rastreadas fitoquimicamente quanto a alcalóides, flavonóides, polifenóis, saponinas, antraquinona, glicosídeos cardíacos, esteróides e terpenóides. Além disso, para atingir o objetivo principal da presente pesquisa, extratos de plantas selecionadas foram testados quanto à atividade antibacteriana in vitrocontra Staphylococcus aureus, Escherichia coli, Shigella spp., Bacillus subtilis, Clavibacter spp., Proteus vulgaris e Salmonella spp. Todas essas bactérias foram isoladas de mastite clínica em vacas leiteiras. Os resultados indicaram que o extrato etanólico da parte aérea de L. virginicum exibia a atividade antimicrobiana mais forte e poderia ser uma espécie potencial candidata ao desenvolvimento de novos medicamentos veterinários com baixo custo e menos efeitos colaterais.
Asunto(s)
Schinus molle , Lepidium , Euphorbia , Mastitis Bovina , Medicina Tradicional , AntibacterianosRESUMEN
No existe estudio que evalúe el estado de la oxigenoterapia en vuelo (OV) en nuestro país. El objetivo de este estudio fue evaluar los requisitos, dificultades, sistemas y costos de la OV de las companías aéreas nacionales (N) e internacionales (I) que operan desde Buenos Aires. Se utilizó la misma encuesta telefónica y metodología que el estudio de Stoller y col.12. Los autores se comunicaron telefónicamente con 25 aerolíneas que operaban en los dos aeropuertos de Buenos Aires en julio de 2007, y se interrogó sobre los requisitos necesarios para viajar, sistemas y costos. Se usaron técnicas estadísticas convencionales siendo significativa p<0.05. De 25 aerolíneas, se descartaron seis (24%) por falta de información (60% de las N y 16% de las I). El 100% de las N permitían la OV vs. 80% de las I (p<0.05). El 100% de las N y 94% de las I exigían certificado médico (p=NS). El 71% de las N requerían de aviso previo vs. 100% de las I (p<0.05). El 50% de las N proveían interfases de administración de oxígeno vs. 87% de las I (p=NS). El 100% de las N disponían del oxígeno sin cargo, vs. 50% de las I (p=NS). El costo oscilaba entre 70 a 300 dólares por escala. En conclusión, se observó una marcada dificultad en la provisión de información de las compañías aéreas, y restricciones de su uso. El costo es muy variable y se da principalmente en las compañías aéreas I. Consideramos necesario implementar acciones que faciliten el acceso de los pacientes y médicos a la información pertinente de cada compañía aérea sobre OV.
There are no data about supplemental oxygen in flight in our country. The objective of our study was to evaluate arranging in-flight-oxygen required by a simulated traveler, system of administration and costs, and to compare the results between Argentine-based (A) and international (I) airlines. The questionnaire used was similar to that of Stoller et al12. Data collection consisted of telephone calls placed by one of the authors to all commercial air carriers listed in our two Buenos Aires City airports during July 2007. A structured interview with questions was addressed on issues that an oxygen-using air traveler would need to arrange in-flight oxygen. Of the 25 airlines, 6 were discarded because of lack of information (24%, three A -60%-and one I-16%-). All A allowed in-flightoxygen vs. 80% of I (p<0.05), 100% of A and 94% of I required a medical certificate (p=NS); 71% of A and 100% of I required previous notification (p<0.05); 50% of A and 87% of I provided patient interphases of oxygen administration (p=NS). Free of charge oxygen could be provided by 100% of A and 50% of I, with airline charge between 70 to 300 dollars. In conclusion, we observed different policies, rules, availability, and a pronounced lack of standardization of airline information. The cost of oxygen was very different between airlines and it was superior on I. It will be necessary to carry out actions to facilitate patient access to oxygentherapy and to standardize medical information among airlines in our country.